Teen OTC drug abuse falls, Rx level steady

22 December 2008

The abuse of over-the-counter cough remedies by US teenagers is falling, according to the National Institute on Drug Abuse's annual Monitoring the Future survey. Linda Suydam, president of the Consumer Healthcare Products Association, which represents OTC drug firms, said: "this year's survey offers very promising news about the efforts of the leading makers of OTC cough medicines to discourage abuse, noting that the annual rates of prevalence have decreased among eighth and 12th graders and show no increase among 10th graders."

Among the CHPA's initiatives to counter the problem, Ms Suydam noted "educational programming for parents, schools, pharmacists and retailers, law enforcement, health professionals, community leaders and on-line."

The National Institutes of Health, which includes the NIDA, reported that the survey "indicates a continuing high rate of prescription drug abuse among teens, with little change seen in the past few years." Seven of the top 10 drugs abused by 12th graders were either prescription or OTC agents, the NIH noted. The most popular of these are opioid painkillers Vicodin (hydrocodone 10mg, paracetamol 1g) and OxyContin (oxycondone HCl), the former co-marketed by drug major Abbott Laboratories and Purdue Frederick.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight